[Form 4] Axon Enterprise, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jeri Williams, a director of Axon Enterprise, Inc. (AXON), received 100 restricted shares on 08/29/2025 that vested in full on the grant date. The award was granted under the company’s Second Amended and Restated 2022 Stock Incentive Plan and carried a reported price of $0. After the transaction, Ms. Williams is reported to beneficially own 1,516 shares of Axon common stock on a direct basis. The Form 4 was signed on behalf of Ms. Williams by an attorney-in-fact on 09/03/2025.

Insights

Securities Analyst

TL;DR: Director received a small, fully vested equity grant, modestly increasing direct holdings; likely neutral for shareholders.

This Form 4 discloses a director-level issuance of 100 restricted shares that vested immediately. The grant was issued under Axon’s 2022 Stock Incentive Plan and reported at a $0 price, consistent with restricted stock unit settlement practices where shares are delivered without a purchase price at vesting. The director’s total direct beneficial ownership after the transaction is 1,516 shares. Given the small size of the grant relative to a public company’s outstanding shares, the transaction appears routine and not material to Axon’s capital structure or control.

Corporate Governance Expert

TL;DR: Routine director equity compensation; transparency maintained through timely Form 4 filing.

The filing shows compliance with Section 16 reporting: the transaction date is 08/29/2025 and the Form 4 was executed by an attorney-in-fact on 09/03/2025. The disclosure identifies the award as restricted stock units under the company’s equity plan with immediate vesting. From a governance perspective, the recordkeeping and disclosure appear standard for executive/director compensation practices, and the immediate vesting should be understood as part of the specific grant terms rather than an ongoing scheduled vesting event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Jeri

(Last) (First) (Middle)

17800 NORTH 85TH STREET

(Street)

SCOTTSDALE AZ 85255

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AXON ENTERPRISE, INC. [ AXON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		A		100(1)	A	$0	1,516	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units pursuant to the Axon Enterprise, Inc. Second Amended and Restated 2022 Stock Incentive Plan. The shares vested in full on the grant date.

Remarks:

	/s/ Jeri Williams, by Isaiah Fields, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AXON director Jeri Williams report on Form 4?

The Form 4 reports that Jeri Williams received 100 restricted shares that vested on 08/29/2025 under the 2022 Stock Incentive Plan.

How many AXON shares does Jeri Williams own after the reported transaction?

Following the transaction, Jeri Williams is reported to beneficially own 1,516 shares of Axon common stock on a direct basis.

Was there a purchase price for the shares reported on the Form 4?

The filing reports a price of $0 for the 100 shares, reflecting delivery upon vesting of restricted stock units.

When was the Form 4 signed for the AXON filing?

The Form 4 signature block shows it was signed by an attorney-in-fact on 09/03/2025.

Under which plan were the shares granted?

The shares were granted pursuant to the Axon Enterprise, Inc. Second Amended and Restated 2022 Stock Incentive Plan.